Abbott NMP22 Bladderchek Rapid Card - Pack of 10 Test (D1300E)

The Abbott NMP22 Bladderchek Rapid Card is an in vitro immunoassay designed for the qualitative detection of nuclear mitotic apparatus protein (NuMA), also known as nuclear matrix protein 22 (NMP22), in human urine. This rapid card test serves as an aid in diagnosing and monitoring bladder cancer patients when used in conjunction with standard diagnostic procedures. It is specifically indicated for persons with risk factors or symptoms of bladder cancer or those with a history of the disease.

The test utilizes a lateral flow immunochromatographic strip encased within a plastic cartridge. The device incorporates colloidal gold particles conjugated to a reporter antibody and a capture monoclonal antibody immobilized on a membrane, facilitating the detection of NMP22 released from bladder tumor cells. This allows for the identification of elevated NMP22 levels in urine, which are associated with bladder carcinoma patients. The test provides rapid results within 30 minutes, enabling healthcare providers to consult with patients during the same visit. When combined with cystoscopy, the NMP22 BladderChek Rapid Card has demonstrated 99% sensitivity for detecting recurrent cancer and an impressive 99% NPV overall for ruling out bladder cancer.

The Abbott NMP22 Bladderchek Rapid Card is CE-Marked and CLIA-Waived, ensuring diagnostic reliability and user-friendliness. It is also FDA-Cleared for both professional point-of-care applications and prescription home use in the United States.

Key Features : 

Qualitative detection of nuclear matrix protein 22 (NMP22) in urine
Aids in the diagnosis and monitoring of bladder cancer
Utilizes lateral flow immunochromatographic technology
CE-Marked and CLIA-Waived
FDA-Cleared for professional and prescription home use